Chimera Investment Corporation Aktie News

NEW YORK--(BUSINESS WIRE)--Chimera Investment Corporation (NYSE: CIM) (the “Company”) announced today that it has closed its previously announced underwritten public offering of $65 million aggregate principal amount of its 9.000% senior notes due 2029 (the “Notes”). The Company has applied to list the Notes on the New York Stock Exchange under the symbol “CIMN” and expects trading in the Notes...

U.S. equity markets climbed to fresh record highs, while benchmark interest rates dipped to one-month lows after a critical slate of inflation and retail sales data showed an unexpected cooldown. Reflecting the mounting quantity of downside economic surprises, the Citi Economic Surprise Index dipped to the lowest level since early 2023, indicating a rather abrupt reversal in economic momentum. ...

NEW YORK--(BUSINESS WIRE)--Chimera Investment Corporation (NYSE: CIM) (the “Company”) announced today the pricing of an underwritten public offering of $65 million aggregate principal amount of its 9.00% senior notes due 2029 (the “Notes”). The Company has granted the underwriters a 30-day option to purchase up to an additional $9.75 million aggregate principal amount of the Notes to cover over...

NEW YORK--(BUSINESS WIRE)--Chimera Investment Corporation (NYSE: CIM) (the “Company” or “Chimera”) announced today that its Board of Directors has unanimously approved a reverse stock split of the Company's common stock at a ratio of 1-for-3. 1-for-3 Reverse Stock Split The reverse stock split is expected to take effect following the close of business on May 21, 2024 (the “Effective Time”). Acc...

Chimera Investment Corporation (NYSE:CIM ) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET Company Participants Victor Falvo - Head of Capital Markets and Investor Relations Phil Kardis - President and Chief Executive Officer Subra Viswanathan - Chief Financial Officer Dan Thakkar - Chief Investment Officer Conference Call Participants Doug Harter - UBS Bose George - KBW Trevor Cranston...

WALTHAM, Mass.--(BUSINESS WIRE)--Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced it will present preclinical proof-of-concept data for the company's MTAC (M6PR Targeting Chimera) protein degrader platform at IMMUNOLOGY™ 2024, the American Association of Immunologists annual meeting taking place May 3-7 in Chicago, Illinois. MTACs ar...

NEW YORK--(BUSINESS WIRE)--Chimera Investment Corporation (NYSE: CIM) (the "Company") announced today that it plans to release its financial results for the first quarter ending March 31,2024 on Thursday, May 9, 2024 prior to 7:00 a.m. EDT. The Company will conduct a conference call and audio webcast to discuss the results on Thursday, May 9, 2024 at 8:30 a.m. EDT. Call-in Number: U.S. Toll Fre...

Every once in a while, a blind squirrel finds a nut. The same can be said about the best $5 stocks.